Management of Pericardial Involvement in Leprosy
Treat pericardial involvement in leprosy patients according to standard pericarditis management protocols with NSAIDs and colchicine, while ensuring appropriate multidrug therapy (MDT) for the underlying leprosy infection, and maintain high clinical suspicion for cardiac tamponade requiring urgent pericardiocentesis. 1
Diagnostic Approach
When pericardial deposits are suspected in a leprosy patient, immediate evaluation should include:
- Transthoracic echocardiography (Class I recommendation) to assess for pericardial effusion and signs of tamponade 1
- Markers of inflammation including CRP to guide treatment duration and assess response 1
- ECG and chest X-ray as part of first-line diagnostic evaluation 1
- CT or CMR if loculated effusion, pericardial thickening, or masses are suspected 1
The case literature documents that cardiac involvement in leprosy, particularly with erythema nodosum leprosum (ENL), can be fatal if not promptly recognized 2. Therefore, any leprosy patient presenting with chest pain, dyspnea, or signs of heart failure requires immediate cardiac evaluation.
Treatment Algorithm
1. Assess for High-Risk Features Requiring Hospitalization
Admit patients with: fever >38°C, large pericardial effusion, cardiac tamponade, or subacute onset 1, 3
2. Emergency Intervention if Tamponade Present
Pericardiocentesis is indicated immediately (Class I) for cardiac tamponade or symptomatic moderate-to-large effusions 1. This is critical as cardiac involvement in leprosy with ENL has proven fatal in documented cases 2.
3. Medical Management for Pericarditis
First-line therapy:
- NSAIDs (aspirin 500-1000 mg every 6-8 hours or ibuprofen 600 mg every 8 hours) for weeks to months 1, 3
- Colchicine 0.5 mg twice daily (or once daily if <70 kg) for 3 months as adjunct therapy (Class I, Level A recommendation) 1, 3
- Taper NSAIDs by 250-500 mg every 1-2 weeks once chest pain resolves and CRP normalizes 1
Avoid corticosteroids as first-line therapy (Class III recommendation) 1. This is particularly important given that corticosteroids favor recurrence and should only be used for specific indications or when NSAIDs/colchicine fail 1.
4. Target the Underlying Etiology
Continue appropriate leprosy MDT throughout cardiac management 4. The pericardial involvement represents either:
- Direct mycobacterial infiltration (pericardial deposits)
- Immune-mediated inflammation from ENL reaction
For ENL-associated pericarditis, standard ENL management may be required alongside cardiac therapy.
5. Monitor for Recurrence
If pericarditis recurs (15-30% risk without colchicine, reduced to approximately 17% with colchicine) 3:
- Extend colchicine to 6 months minimum 1
- Continue NSAIDs with appropriate tapering
- Consider corticosteroids only as triple therapy (added to NSAIDs + colchicine, not replacing them) at low-to-moderate doses (prednisone 0.2-0.5 mg/kg/day) 1
Critical Pitfalls to Avoid
Do not delay pericardiocentesis in tamponade—this is a Class I indication and the documented case of fatal cardiac involvement in leprosy with ENL emphasizes the urgency 2.
Do not use corticosteroids first-line—they increase recurrence rates despite providing rapid symptom control 1. The ESC guidelines explicitly recommend against this (Class III) 1.
Do not undertreated the initial episode—inadequate treatment duration is a common cause of recurrence 1. Use CRP normalization to guide therapy duration 1.
Do not forget the underlying leprosy treatment—pericardial involvement does not change the need for appropriate MDT, though high-dose prolonged therapy has adherence challenges 4.
Prognosis Considerations
The prognosis depends primarily on:
- Etiology: Infectious causes (including mycobacterial) carry higher risk of constrictive pericarditis (20-30%) compared to idiopathic/viral (<1%) 1
- Effusion size: Large effusions have 30-35% risk of progression to tamponade if chronic 1
- Prompt treatment: With appropriate NSAIDs and colchicine, 70-85% of pericarditis patients have a benign course 3
Given that leprosy represents a specific infectious etiology with documented cardiac fatalities 2, these patients warrant closer monitoring than typical idiopathic pericarditis cases.